Throughout my career, I have been driven by a fundamental belief that scientific discoveries achieve their greatest impact when they improve patient care. While academic research plays a critical role in generating new knowledge, I have always been motivated by the challenge of translating innovative technologies from the laboratory into practical clinical solutions. This translational journey—from concept and prototype to commercialization and clinical adoption—has been a central theme of my work as an engineer, researcher, entrepreneur, and startup leader.
My experience at Dartmouth provided a unique environment for pursuing this mission. Working at the intersection of engineering, medicine, and clinical practice, I was able to collaborate with physicians, scientists, and fellow engineers to identify unmet needs in cancer diagnosis, imaging, and treatment. These collaborations often generated promising technologies, but I quickly learned that creating a successful innovation requires much more than scientific excellence. Transforming a laboratory discovery into a product that can be used in hospitals and clinics demands persistence, business strategy, regulatory navigation, financial investment, and a willingness to embrace risk.
One of the most rewarding aspects of my career has been helping launch and guide startup companies focused on advancing medical technologies. Startups serve as a critical bridge between academic research and clinical implementation. They provide the structure, resources, and focus necessary to move technologies beyond proof-of-concept studies and toward products that can reach patients. Through my leadership roles in multiple startup ventures, I have gained firsthand experience with the opportunities and challenges that accompany technology commercialization.
The startup environment is fundamentally different from academia. In a university setting, researchers can focus primarily on scientific discovery and publication. In contrast, startup leaders must simultaneously address technical development, intellectual property protection, regulatory requirements, manufacturing considerations, fundraising, market analysis, and customer adoption. Success depends not only on whether a technology works, but whether it solves a meaningful clinical problem in a cost-effective and scalable manner.
One of the earliest lessons I learned as an entrepreneur was the importance of understanding the clinical workflow. Engineers often become excited about technical innovation, but healthcare providers ultimately evaluate technologies based on their ability to improve patient outcomes and integrate smoothly into existing clinical practices. This realization reinforced the importance of maintaining close partnerships with physicians throughout the development process. By involving clinicians early and often, our teams were able to refine technologies based on real-world needs and increase the likelihood of successful adoption.
Another significant challenge in translating medical technologies is securing the financial resources necessary to support development. Medical device and healthcare technology startups frequently require substantial investment over many years before reaching commercialization. As a startup leader, I have participated in fundraising efforts, investor discussions, strategic planning, and business development activities designed to sustain innovation through lengthy development cycles. These experiences taught me that successful commercialization requires communicating not only the scientific merit of a technology but also its clinical value and market potential.
Regulatory approval represents another major hurdle in the commercialization process. Healthcare technologies must meet rigorous standards for safety, efficacy, and quality before they can be deployed in clinical settings. Navigating these requirements requires expertise that extends far beyond engineering and science. Throughout my startup experiences, I have worked closely with regulatory specialists, clinical investigators, and industry partners to develop strategies for demonstrating performance and meeting regulatory expectations. Although these processes can be complex and time-consuming, they are essential for ensuring that new technologies ultimately benefit patients safely and effectively.
Despite these challenges, the rewards of successful technology translation are extraordinary. Few experiences compare to seeing a technology that began as a research concept evolve into a tool that helps physicians diagnose disease more accurately, guide treatment decisions, or improve surgical outcomes. These moments serve as powerful reminders of why commercialization efforts matter. The ultimate goal is not simply to create innovative technology but to create meaningful impact for patients and healthcare providers.
My work in imaging science, image-guided intervention, and cancer-related technologies has consistently reinforced the importance of multidisciplinary collaboration throughout the commercialization process. Successful startups require expertise from engineers, clinicians, business professionals, investors, regulatory specialists, and manufacturing experts. No single individual possesses all the knowledge needed to bring a complex medical technology to market. Building strong teams and fostering collaborative environments has therefore been one of the most important aspects of my entrepreneurial journey.
Looking ahead, I believe the opportunities for translating medical technologies into clinical practice are greater than ever. Advances in computational modeling, artificial intelligence, imaging systems, and data analytics are creating new possibilities for personalized medicine and cancer care. However, realizing these opportunities will require continued collaboration between academia, healthcare institutions, industry, and entrepreneurial ventures. My experiences in both research and startup leadership have convinced me that innovation thrives when talented individuals from diverse backgrounds work together toward a common goal.
Ultimately, my entrepreneurial journey has taught me that innovation is not complete until it reaches the patient. The process of translating technology from the laboratory to the clinic is challenging, demanding, and often unpredictable, but it is also deeply rewarding. Through my involvement in startup companies and commercialization efforts, I have had the privilege of helping move promising technologies closer to clinical reality, contributing to advances that have the potential to improve healthcare and make a meaningful difference in people’s lives.
